{"id":93177,"date":"2026-07-02T11:44:12","date_gmt":"2026-07-02T11:44:12","guid":{"rendered":"https:\/\/www.europesays.com\/ai\/93177\/"},"modified":"2026-07-02T11:44:12","modified_gmt":"2026-07-02T11:44:12","slug":"china-ai-drug-design-deals-swell-as-us-scrutiny-mounts-2","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/ai\/93177\/","title":{"rendered":"China AI drug-design deals swell as US scrutiny mounts"},"content":{"rendered":"<p datatype=\"p\" data-qa=\"Component-Component\" class=\"e8zc9q40 css-1c6uqr6 ec74h0k1\">Riding a wave of booming cross-border dealmaking, China\u2019s AI-driven drug-design firms are charging onto the global stage despite Washington\u2019s growing scrutiny of Chinese biotech firms.<\/p>\n<p datatype=\"p\" data-qa=\"Component-Component\" class=\"e8zc9q40 css-1c6uqr6 ec74h0k1\">The value of out-licensing deals struck by Chinese biotech companies with top global multinational pharmaceutical companies climbed to US$75 billion in the first five months of 2026, up from zero before 2020, according to Linda Shu, head of China healthcare research at HSBC.<\/p>\n<p datatype=\"p\" data-qa=\"Component-Component\" class=\"e8zc9q40 css-1c6uqr6 ec74h0k1\">In total, over the five months, these firms struck 169 licensing deals \u2013 worth a combined US$93 billion and marking an 87 per cent jump from a year earlier, Shu said in a note on Friday.<\/p>\n<p>The latest example came on Tuesday. Less than two months after its <a target=\"_self\" class=\"e1yy41x40 ef9u0v01 css-1ankfgb ecgc78b0\" href=\"https:\/\/www.scmp.com\/business\/banking-finance\/article\/3353341\/hong-kong-biotech-firm-uses-ai-produce-nano-rockets-deliver-life-saving-drugs?module=inline&amp;pgtype=article\" title=\"\" data-qa=\"BaseLink-renderAnchor-StyledAnchor\" rel=\"nofollow noopener\">Hong Kong stock market debut<\/a>, Metis TechBio, an AI-driven drug-design company with operations in China and the United States, signed a cross-border agreement with Boulevard Bio, a biotechnology company backed by New York investment firm Deerfield Management, according to a filing with the Hong Kong stock exchange on the same day.<\/p>\n<p datatype=\"p\" data-qa=\"Component-Component\" class=\"e8zc9q40 css-1c6uqr6 ec74h0k1\">Under the deal, Metis TechBio was expected to receive an upfront payment of US$20 million and was eligible for up to US$1.6 billion in development, regulatory and commercial milestone payments, plus tiered royalties on future product sales.<\/p>\n<p datatype=\"p\" data-qa=\"Component-Component\" class=\"e8zc9q40 css-1c6uqr6 ec74h0k1\">In return, Boulevard Bio gained global rights to develop, manufacture and commercialise MTS-128, Metis TechBio\u2019s next-generation cancer-fighting drug candidate powered by artificial intelligence.<\/p>\n<p>US adds Alibaba, BYD, Baidu and other Chinese tech giants to military blacklist<\/p>\n","protected":false},"excerpt":{"rendered":"Riding a wave of booming cross-border dealmaking, China\u2019s AI-driven drug-design firms are charging onto the global stage despite&hellip;\n","protected":false},"author":2,"featured_media":93160,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[2],"tags":[24,48862,25,23236,48861,387,48863,48860,15441,2700,6658,6505,48857,214,48859,2187,48858],"class_list":["post-93177","post","type-post","status-publish","format-standard","has-post-thumbnail","category-ai","tag-ai","tag-ailux","tag-artificial-intelligence","tag-astrazeneca","tag-boulevard-bio","tag-china","tag-cspc-pharmaceutical-group","tag-deerfield-management","tag-eli-lilly","tag-hong-kong","tag-hsbc","tag-metis-techbio","tag-mts-128","tag-united-states","tag-us-biotech-investment-national-security-act","tag-washington","tag-xtalpi-holdings"],"_links":{"self":[{"href":"https:\/\/www.europesays.com\/ai\/wp-json\/wp\/v2\/posts\/93177","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/ai\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/ai\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ai\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ai\/wp-json\/wp\/v2\/comments?post=93177"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/ai\/wp-json\/wp\/v2\/posts\/93177\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ai\/wp-json\/wp\/v2\/media\/93160"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/ai\/wp-json\/wp\/v2\/media?parent=93177"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/ai\/wp-json\/wp\/v2\/categories?post=93177"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/ai\/wp-json\/wp\/v2\/tags?post=93177"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}